{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:15Z","timestamp":1791828855169,"version":"4.3.4"},"reference-count":151,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA)-related comorbidities, including cardiovascular disease (CVD), osteoporosis (OP), and interstitial lung disease (ILD), are sub-optimally managed. RA-related comorbidities affect disease control and lead to impairment in quality of life. We aimed to develop consensus recommendations for managing RA-related comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The consensus statements were formulated based on emerging evidence during a face-to-face meeting of Taiwan rheumatology experts and modified through three-round Delphi exercises. The quality of evidence and strength of recommendation of each statement were graded after a literature review, followed by voting for agreement. Through a review of English-language literature, we focused on the existing evidence of management of RA-related comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Based on experts\u2019 consensus, eleven recommendations were developed. CVD risk should be assessed in patients at RA diagnosis, once every 5\u200ayears, and at changes in DMARDs therapy. Considering the detrimental effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids on CVD risks, we recommend using the lowest possible dose of corticosteroids and prescribing NSAIDs cautiously. The OP\/fragility fracture risk assessment includes dual-energy X-ray absorptiometry and fracture risk assessment (FRAX) in RA. The FRAX-based approach with intervention threshold is a useful strategy for managing OP. RA-ILD assessment includes risk factors, pulmonary function tests, HRCT imaging and a multidisciplinary decision approach to determine RA-ILD severity. A treat-to-target strategy would limit RA-related comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These consensus statements emphasize that adequate control of disease activity and the risk factors are needed for managing RA-related comorbidities, and may provide useful recommendations for rheumatologists on managing RA-related comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000028501","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T08:21:30Z","timestamp":1641543690000},"page":"e28501","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":41,"title":["Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis"],"prefix":"10.1097","volume":"101","author":[{"given":"Kuang-Hui","family":"Yu","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Chang Gung University and Memorial Hospital, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taichung Veterans General Hospital, Taiwan"},{"name":"Faculty of Medicine, National Yang Ming University, Taipei, Taiwan"},{"name":"Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung, Taiwan"},{"name":"Institute of Biomedicine Science, National Chung Hsing University, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Tsai","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Chang Gung University and Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Jian","family":"Jan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Chang Gung University and Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yu","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, National Cheng Kung University Medical College and Hospital."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Jang","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-An","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Tseng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Kaohsiung Veterans General Hospital, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yung","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Immunology, Allergy and Rheumatology, Buddhist Tzu Chi Medical Foundation, Dalin Tzu Chi Hospital, Chiayi, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien City, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko-Jen","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology, Department of Internal Medicine, National Taiwan University Hospital"},{"name":"College of Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jih","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taichung Veterans General Hospital, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui-Ying","family":"Leong","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan"},{"name":"Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chan","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung-Liang","family":"Lan","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-2235","authenticated-orcid":false,"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan"},{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"R3-20250504","first-page":"154","article-title":"Co-morbidities in rheumatoid arthritis: analysis of hospital discharge records","volume":"57","author":"Parodi","year":"2005","journal-title":"Reumatismo"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/ar2669","article-title":"Epidemiological studies in incidence, prevalence, mortality and comorbidity of the rheumatic diseases","volume":"11","author":"Gabriel","year":"2009","journal-title":"Arthritis Res Thera"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard.2008.098038","article-title":"Why do people with rheumatoid arthritis still die prematurely?","volume":"67","author":"Gabriel","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/acr.22108","article-title":"Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity","volume":"66","author":"Tymms","year":"2014","journal-title":"Arthritis Care Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Whole EULAR task force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41927-018-0039-2","article-title":"The extra-articular impacts of rheumatoid arthritis: moving towards holistic care","volume":"2","author":"Scott","year":"2018","journal-title":"BMC Rheumatology"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","article-title":"Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis","volume":"52","author":"Ranganath","year":"2013","journal-title":"Rheumatology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/acr.23178","article-title":"Primary care screening and comorbidities management in rheumatoid arthritis on Ontario, Canada","volume":"69","author":"Widdifield","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2011.75","article-title":"Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE","volume":"7","author":"Symmons","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R17-20250504","first-page":"804","article-title":"Predictors of fractures in early rheumatoid arthritis","volume":"18","author":"Michel","year":"1991","journal-title":"J Rheumatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","article-title":"Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis","volume":"43","author":"Haugeberg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-014-2968-y","article-title":"Rheumatoid arthritis patients with hip fracture: a nationwide study","volume":"26","author":"Lin","year":"2015","journal-title":"Osteoporosis Int"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1183\/09059180.00008014","article-title":"Rheumatoid arthritis-associated lung disease","volume":"24","author":"Shaw","year":"2015","journal-title":"Eur Respir Rev"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/ar3097","article-title":"Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management","volume":"12","author":"Castelino","year":"2010","journal-title":"Arthritis Res Thera"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R26-20250504","first-page":"36","article-title":"Clinical characteristics of rheumatoid arthritis-associated lung disease: a retrospective study in a tertiary referral center in Taiwan","volume":"32","author":"Chang","year":"2018","journal-title":"Formosan J Rheumatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jbspin.2006.01.014","article-title":"Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"Pham","year":"2006","journal-title":"Joint Bone Spine"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00296-014-3196-7","article-title":"Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis","volume":"35","author":"Loza","year":"2015","journal-title":"Rheumatol Int"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jbspin.2016.05.012","article-title":"Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic disease in daily practice","volume":"83","author":"Gossec","year":"2016","journal-title":"Joint Bone Spine"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3899\/jrheum.141112","article-title":"Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative","volume":"42","author":"Roubille","year":"2015","journal-title":"J Rheumatol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/annrheumdis-2016-210289","article-title":"EULAR\/EFFORT recommendations for management of patients older than 50\u200ayears with a fragility fracture and prevention of subsequent fractures","volume":"76","author":"Lems","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10067-015-3142-4","article-title":"Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis","volume":"35","author":"EI-Zorkany","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Oxman","year":"2004","journal-title":"Brit Med J"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","author":"Lindhardsen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \u201chighgrade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"R37-20250504","first-page":"1219","article-title":"High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis","volume":"32","author":"Gonzalez-Gay","year":"2005","journal-title":"J Rheumatol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.25009","article-title":"Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis","volume":"61","author":"Rho","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avina-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/acr.22419","article-title":"Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systemic review of guideline recommendations and quality indicators","volume":"67","author":"Barber","year":"2015","journal-title":"Arthritis Care Res"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/rheumatology\/ken450a","article-title":"British Society for Rheumatology; British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2\u200ayears)","volume":"48","author":"Luqmani","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.semarthrit.2017.08.002","article-title":"Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis","volume":"47","author":"Cho","year":"2018","journal-title":"Seminars Arthritis Rheum"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","article-title":"Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systemic review and meta-analysis","volume":"77","author":"Rempenault","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41927-018-0014-y","article-title":"Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular assessment and treatment","volume":"2","author":"Jagpal","year":"2018","journal-title":"BMC Rheumatol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systemic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/1756-185X.13611","article-title":"Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: a nationwide population-based cohort study in Taiwan","volume":"22","author":"Tang","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/acr.23737","article-title":"Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients","volume":"71","author":"Xie","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/rheumatology\/keu376","article-title":"Inflammatory burden interacts with conventional cardiovascular risk factors for carotid plaque formation in rheumatoid arthritis","volume":"54","author":"Im","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/1756-185X.12999","article-title":"New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis","volume":"20","author":"Mahmoudi","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jbspin.2010.07.016","article-title":"Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis","volume":"78","author":"Boyer","year":"2011","journal-title":"Joint Bone Spine"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kex038","article-title":"Trans-Atlantic cardiovascular consortium for rheumatoid arthritis. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries","volume":"56","author":"Crowson","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R58-20250504","first-page":"1766","article-title":"Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem","volume":"33","author":"Soubrier","year":"2006","journal-title":"J Rheumatol"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/acr.21935","article-title":"RHEVER Rheumatology Network. The challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting. An observational study of the 110 rheumatoid arthritis patients","volume":"65","author":"Gossec","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/ard.2010.142455","article-title":"Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study","volume":"70","author":"De Vera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"03","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/acr.22722","article-title":"Prednisone use and risk of mortality in patients with rheumatoid arthritis: moderation by use of disease-modifying antirheumatic drugs","volume":"68","author":"Wasko","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R63-20250504","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/phar.1584","article-title":"Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease","volume":"35","author":"Danelich","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R64-20250504","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/jbmr.2221","article-title":"Alterations of bone density, microstructure, and strength of the distal radius in male patients with rheumatoid arthritis: a case-control study with HR-pQCT","volume":"29","author":"Zhu","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R65-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-018-1515-1","article-title":"Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX: a registry study of RA with osteoporosis\/fracture","volume":"20","author":"Cheng","year":"2018","journal-title":"Arthritis Res Thera"},{"key":"R66-20250504","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/art.27252","article-title":"Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography","volume":"62","author":"Stach","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R67-20250504","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1136\/annrheumdis-2014-205428","article-title":"Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA","volume":"74","author":"Hecht","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R68-20250504","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/jbmr.3158","article-title":"Periarticular bone loss in arthritis is induced by autoantibodies against citrullinated vimentin","volume":"32","author":"Engdahl","year":"2017","journal-title":"Bone Miner Res"},{"key":"R69-20250504","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","article-title":"Bone mineral density and frequency of opteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register","volume":"43","author":"Haugeberg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R70-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/RHU.0000000000000359","article-title":"Bone mineral density in patients with rheumatoid arthritis and 4-year follow-up results","volume":"22","author":"Peng","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"R71-20250504","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","article-title":"Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register","volume":"43","author":"Haugeberg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R72-20250504","doi-asserted-by":"crossref","first-page":"R154","DOI":"10.1186\/ar3107","article-title":"Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis","volume":"12","author":"Kim","year":"2010","journal-title":"Arthritis Res Thera"},{"key":"R73-20250504","first-page":"32","article-title":"Generalized osteoporosis in Korean rheumatoid arthritis patients","volume":"7","author":"Joo","year":"2000","journal-title":"J Korean Rheum Assoc"},{"key":"R74-20250504","first-page":"01","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ","volume":"843","year":"1994","journal-title":"Tech Rep Ser"},{"key":"R75-20250504","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"issue":"(Suppl 2)","key":"R76-20250504","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1007\/s00198-010-1253-y","article-title":"Development and use of FRAX in osteoporosis","volume":"21","author":"Kanis","year":"2010","journal-title":"Osteoporos Int"},{"key":"R77-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"R78-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","article-title":"the Advisory Board of the National Osteoporosis Guideline Group: a systemic review of intervention thresholds based on FRAX. A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation","volume":"11","author":"Kanis","year":"2016","journal-title":"Arch Osteoporosis"},{"key":"R79-20250504","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R80-20250504","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","article-title":"Adherence and profile of nonpersistence in patients treated for osteoporosis\u2013a large-scale, long-term retrospective study in the Netherlands","volume":"22","author":"Netelenbos","year":"2011","journal-title":"Osteoporos Int"},{"key":"R81-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"key":"R82-20250504","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/annrheumdis-2019-215328","article-title":"Medications associated with fracture risks in patients with rheumatoid arthritis","volume":"78","author":"Ozen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R83-20250504","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/RHU.0b013e3181a5679d","article-title":"Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) Registry","volume":"15","author":"Coulson","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"R84-20250504","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","article-title":"Guidance for the adjustment of FRAX according to the dose of glucocorticoids","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporosis Int"},{"key":"R85-20250504","first-page":"CD001347","article-title":"Bisphosphonates for steroid-induced osteoporosis","volume":"10","author":"Allen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R86-20250504","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"R87-20250504","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R88-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.2003.005850","article-title":"Self-reported nonvertebral fractures in rheumatoid arthritis and population-based controls: incidence and relationship with bone mineral density and clinical variables","volume":"63","author":"\u00d8rstavik","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R89-20250504","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/rheumatology\/ket353","article-title":"The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis","volume":"53","author":"Mohammad","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R90-20250504","doi-asserted-by":"crossref","first-page":"e6677","DOI":"10.1097\/MD.0000000000006677","article-title":"Evaluating osteoporotic fracture risk with the Fracture Risk Assessment Tool in Chinese patients with rheumatoid arthritis","volume":"96","author":"Meng","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R91-20250504","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s10067-018-4218-8","article-title":"The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis","volume":"37","author":"Phuan-udom","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R92-20250504","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14656566.2015.997709","article-title":"Management of osteoporosis in rheumatoid arthritis patients","volume":"16","author":"Hoes","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R93-20250504","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s40266-019-00714-4","article-title":"Pharmacological management of osteoporosis in rheumatoid arthritis patients: a review of literature and practical guide","volume":"36","author":"Raterman","year":"2019","journal-title":"Drugs and Aging"},{"key":"R94-20250504","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/acr.22752","article-title":"Rheumatoid arthritis and mortality among women during 36\u200ayears of prospective follow-up: results from the nurses\u2019 health study","volume":"68","author":"Sparks","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R95-20250504","first-page":"280","article-title":"Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis: shared mechanistic and phenotypic traits suggest overlapping disease mechanisms","volume":"67","author":"Paulin","year":"2015","journal-title":"Rev Investing Clin"},{"key":"R96-20250504","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers","volume":"191","author":"Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R97-20250504","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis","volume":"156","author":"Gabbay","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"R98-20250504","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10067-017-3561-5","article-title":"Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease","volume":"36","author":"Zhang","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R99-20250504","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.semarthrit.2020.07.011","article-title":"Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: a nationwide, population-based cohort study","volume":"50","author":"Ng","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R100-20250504","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.2006.054445","article-title":"Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis","volume":"66","author":"Turesson","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R101-20250504","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s10067-015-3025-8","article-title":"Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis","volume":"34","author":"Restrepo","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R102-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/BOR.0000000000000380","article-title":"Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"29","author":"Johnson","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R103-20250504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11926-017-0701-5","article-title":"Rheumatoid arthritis-associated interstitial lung disease: current concepts","volume":"19","author":"Brito","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"R104-20250504","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/OARRR.S166070","article-title":"Current perspectives on emerging biomarkers for rheumatoid arthritis-associated interstitial ling disease","volume":"11","author":"Amigues","year":"2019","journal-title":"Open Access Rheumatol"},{"key":"R105-20250504","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1148\/radiol.2321030174","article-title":"Rheumatoid arthritis-related lung disease: CT findings","volume":"232","author":"Tanaka","year":"2004","journal-title":"Radiology"},{"key":"R106-20250504","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner society: glossary of terms for thoracic imaging","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology"},{"key":"R107-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40744-017-0071-5","article-title":"Practical management of respiratory comorbidities in patients with rheumatoid arthritis","volume":"4","author":"Bluett","year":"2017","journal-title":"Rheumatol Ther"},{"key":"R108-20250504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrrheum.2013.197","article-title":"The safety of biologic therapies in RA-associated interstitial lung disease","volume":"10","author":"Jani","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R109-20250504","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"ATS\/ERS committee on idiopathic interstitial pneumonias. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R110-20250504","doi-asserted-by":"crossref","first-page":"1800869","DOI":"10.1183\/13993003.00869-2018","article-title":"Predicting outcomes in rheumatoid arthritis related interstitial lung disease","volume":"53","author":"Jacob","year":"2019","journal-title":"Eur Respir J"},{"key":"R111-20250504","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"key":"R112-20250504","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.rmed.2017.03.027","article-title":"High resolution tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: relationship to survival","volume":"126","author":"Yunt","year":"2017","journal-title":"Respir Med"},{"key":"R113-20250504","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicenter UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R114-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1002\/art.39480","article-title":"American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis rheumatol"},{"key":"R115-20250504","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/art.1780261015","article-title":"Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis","volume":"26","author":"Cannon","year":"1983","journal-title":"Arthritis Rheum"},{"key":"R116-20250504","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R117-20250504","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00296-020-04773-4","article-title":"Does methotrexate cause progressive fibrotic interstitial lung disease? A systemic review","volume":"41","author":"Dawson","year":"2021","journal-title":"Rheumatol Int"},{"key":"R118-20250504","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2169\/internalmedicine.43.1201","article-title":"Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction","volume":"43","author":"Kamata","year":"2004","journal-title":"Intern Med"},{"key":"R119-20250504","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1517\/14740338.2011.560835","article-title":"Leflunomide-induced interstitial pneumonitis might be a representative of diseasemodifying antirheumatic drug-induced lung injury","volume":"10","author":"Inokuma","year":"2011","journal-title":"Exp Opin Drug Saf"},{"key":"R120-20250504","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/rheumatology\/kep052","article-title":"Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology. Leflunomide induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis","volume":"48","author":"Sawada","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R121-20250504","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R122-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-009-0931-6","article-title":"Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment","volume":"30","author":"Taki","year":"2009","journal-title":"Rheumatol Int"},{"key":"R123-20250504","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","article-title":"Postmarketing surveillance of the safety and effectiveness of etanercept in Japan","volume":"36","author":"Koike","year":"2009","journal-title":"J Rheumatol"},{"key":"R124-20250504","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1183\/09059180.00002013","article-title":"Severe interstitial lung disease following treatment with certolizumab pegol: a case report","volume":"22","author":"Lager","year":"2013","journal-title":"Eur Respir Rev"},{"key":"R125-20250504","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MCP.0b013e3283483ea5","article-title":"Biological treatments and connective tissue disease associated interstitial lung disease","volume":"17","author":"Panopoulos","year":"2011","journal-title":"Curr Opin Pulmon Med"},{"key":"R126-20250504","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R127-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pds.3409","article-title":"Association between anti-TNF-\u03b1 therapy and interstitial lung disease","volume":"22","author":"Herrinton","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R128-20250504","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X15612250","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective view","volume":"7","author":"Iqbal","year":"2015","journal-title":"Ther Adv Musculoskel Dis"},{"key":"R129-20250504","first-page":"235","article-title":"Practical approach to the evaluation and management of rheumatoid arthritis-interstitial lung disease: based on its proven and hypothetic mechanisms","volume":"69","author":"Paulin","year":"2017","journal-title":"Rev Invest Clin"},{"key":"R130-20250504","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/art.21758","article-title":"Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis\u2013associated nonspecific interstitial pneumonia and usual interstitial pneumonia","volume":"54","author":"Atkins","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R131-20250504","first-page":"1496","article-title":"AB0800 Safety and clinical response to rituximab in patients with connective tissue disease-associated interstitial lung disease: preliminary results","volume":"71","author":"Romero","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R132-20250504","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern Med J"},{"key":"R133-20250504","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00296-012-2587-x","article-title":"Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience","volume":"33","author":"Braun-Moscovici","year":"2013","journal-title":"Rheumatology Int"},{"key":"R134-20250504","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10-year experience at single center","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R135-20250504","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: Data from the NEREA Registry","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R136-20250504","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-8-7","article-title":"Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease","volume":"10","author":"Vacchi","year":"2021","journal-title":"Drugs Context"},{"key":"R137-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients","volume":"48","author":"Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R138-20250504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/jcm9010277","article-title":"Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"R139-20250504","doi-asserted-by":"crossref","first-page":"102830","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systemic literature review","volume":"20","author":"Vicente-Rabaneda","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R140-20250504","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","article-title":"Non-infectious pulmonary complications of newer biological agents for rheumatic diseases\u2013a systematic literature review","volume":"50","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R141-20250504","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14397595.2018.1481566","article-title":"Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept","volume":"29","author":"Mochizuki","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R142-20250504","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/jcm9041082","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"R143-20250504","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.3390\/jcm10173806","article-title":"Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"10","author":"Yamakawa","year":"2021","journal-title":"J Clin Med"},{"key":"R144-20250504","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The lung in rheumatoid arthritis: focus on interstitial lung disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R145-20250504","first-page":"CD010908","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R146-20250504","first-page":"01","article-title":"Interstitial lung disease in rheumatoid arthritis: a review","volume":"7","author":"Chan","year":"2013","journal-title":"Arth Res Top Rev Ser"},{"key":"R147-20250504","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MCP.0000000000000600","article-title":"New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern?","volume":"25","author":"Morisset","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"R148-20250504","doi-asserted-by":"crossref","first-page":"101051","DOI":"10.1016\/j.rmcr.2020.101051","article-title":"Pirfenidone for the treatment of interstitial lung disease associated with rheumatoid arthritis: a new scenario is coming?","volume":"30","author":"Cassone","year":"2020","journal-title":"Respiratory Medicine Case Reports"},{"key":"R149-20250504","doi-asserted-by":"crossref","first-page":"143637","DOI":"10.1155\/2012\/143637","article-title":"Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis","volume":"2012","author":"Tzouvelekis","year":"2012","journal-title":"Pulm Med"},{"key":"R150-20250504","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","article-title":"Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug","volume":"168","author":"Saketkoo","year":"2008","journal-title":"Arch Intern Med"},{"key":"R151-20250504","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects","volume":"337","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"R152-20250504","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1517\/14656560802591430","article-title":"Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease","volume":"9","author":"Kelly","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R153-20250504","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1469-0691.2005.01337.x","article-title":"Pneumocystis jirovecii colonization in patients with interstitial lung disease","volume":"12","author":"Vidal","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"R154-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/17476348.2015.1002471","article-title":"Prophylaxis for Pneumocystis jirovecii pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?","volume":"9","author":"Liebling","year":"2015","journal-title":"Expert Rev Respir Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:12:10Z","timestamp":1746317530000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028501","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"2020-06-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}